On 17 July 2017, orphan designation (EU/3/17/1890) was granted by the European Commission to Celgene Europe Limited, United Kingdom, for autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor (also known as JCAR017) for the treatment of diffuse large B-cell lymphoma.

The sponsorship was transferred to Celgene Europe B.V., the Netherlands, in February 2019.

The sponsorship was transferred to Bristol-Myers Squibb Pharma EEIG, Ireland in January 2021.

This medicine is now known as lisocabtagene maraleucel.

Key facts

Active substance
Autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor (lisocabtagene maraleucel)
Disease / condition
Treatment of diffuse large B-cell lymphoma
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Bristol-Myers Squibb Pharma EEIG
Plaza 254
Blanchardstown Corporate Park 2
Dublin 15
D15 T867
Tel. +44 (0) 208 831 8327

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating